Chikungunya Vaccine Market Size was valued at USD 0.25 billion in 2022. The Chikungunya Vaccine market industry is projected to grow from USD 0.27 Billion in 2023 to USD 0.49 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.12% during the forecast period (2023 - 2030).
Chikungunya, a viral disease transmitted by mosquitoes, has emerged as a global health concern in recent years. The infection causes severe joint pain, fever, rash, and fatigue, leading to substantial morbidity and impaired quality of life. With the absence of a specific treatment for Chikungunya, prevention through vaccination has become crucial. The Chikungunya vaccine market is witnessing remarkable growth as researchers and pharmaceutical companies race to develop effective immunization strategies against this debilitating disease.
The Burden of Chikungunya:
Chikungunya has rapidly spread across regions, including Africa, Asia, the Americas, and Europe, affecting millions of people worldwide. The disease's burden is not limited to developing nations; it has also been reported in developed countries due to increasing international travel and the expansion of mosquito vectors. The lack of immunity and the absence of an effective treatment underscore the urgency of developing a Chikungunya vaccine.
Growing Investments and Collaborations:
In recent years, there has been a significant increase in investments and collaborations aimed at developing a safe and efficacious Chikungunya vaccine. Governments, non-profit organizations, and pharmaceutical companies are joining forces to expedite vaccine research and development. These partnerships provide essential funding, expertise, and resources necessary for advancing vaccine candidates through preclinical and clinical trials.
Chikungunya Vaccine Market Segmentation
Chikungunya Vaccine Product Technology Outlook (USD Million, 2018-2030)
- Live-Attenuated Virus Vaccines
- Inactivated Viral Vaccine
- Recombinant Viral Vaccines
- Chimeric-Alphavirus Candidates
Chikungunya Vaccine Age Group Outlook (USD Million, 2018-2030)
Chikungunya Vaccine Distribution Channel Outlook (USD Million, 2018-2030)
- Hospital Pharmacies
- Retail Pharmacies
Chikungunya Vaccine Regional Outlook (USD Billion, 2018-2030)
North America, US, Canada, Europe, Germany, France, UK, Italy, Spain, Rest of Europe
Asia-Pacific- China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific
Rest of the World- Middle East, Africa, Latin America
Global Market Potential:
The global Chikungunya vaccine market overview is expected to experience substantial growth in the coming years. Factors such as increasing awareness, rising incidence of Chikungunya, and the demand for preventive measures against mosquito-borne diseases contribute to market expansion. Additionally, government initiatives, public health campaigns, and vaccination programs targeting endemic regions are anticipated to drive the market growth further.
The Chikungunya Vaccine market include
Takeda Pharmaceutical Company Limited (Japan), Valneva SE (France), Moderna Inc (China), Emergent BioSolutions Inc (U.S.), Bharat Biotech International Limited (India), Themis Bioscience GmbH (Austria), Auro Vaccine LLC (U.S.)
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013